Real-world treatment (tx) patterns, cost, and overall survival (OS) by line of therapy among patients (pt) with mantle cell lymphoma (MCL): A SEER-Medicare (SM) analysis.
| Publicado en: | Journal of Clinical Oncology Vol. 40; pp. 19 - 20 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2022 Supplement 28
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159446026&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 159446026 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2022 Supplement 28 vid: 40 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 159446026 10.1200/JCO.2022.40.28_suppl.019 159446026 ppf: 19 ppct: 1 formats: tig: atl: Real-world treatment (tx) patterns, cost, and overall survival (OS) by line of therapy among patients (pt) with mantle cell lymphoma (MCL): A SEER-Medicare (SM) analysis. aug: au: Keating, Scott J. Rege, Sanika McBride, Ali Shah, Ruchit Qian, Joyce Chirikov, Viktor affil: Bristol-Myers Squibb Research, Princeton, NJ sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|